Citations (1)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Zhengyang Fei, Mingjun Rui, Yingcheng Wang & Aixia Ma. (2023) Cost-effectiveness of anlotinib vs. pembrolizumab and nivolumab as third-line treatment in recurrent small cell lung cancer in China. Expert Review of Pharmacoeconomics & Outcomes Research 23:1, pages 79-87.
Read now
Read now